Currently, Ionis Pharmaceuticals Inc [IONS] is trading at $35.59, down -1.82%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IONS shares have lost -3.84% over the last week, with a monthly amount glided 5.45%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on August 02, 2024, when BMO Capital Markets downgraded its rating to a Market Perform and also revised its price target to $60 from $67. Previously, Leerink Partners upgraded its rating to Outperform on July 24, 2024, and elevated its price target to $62. Bernstein upgraded its rating to a Mkt Perform but stick to its price target of $44 on June 14, 2024. Wolfe Research upgraded its rating to a Outperform but $58 remained the price target by the analyst firm on April 10, 2024. BofA Securities upgraded its rating to Buy for this stock on January 02, 2024, and upped its price target to $62. In a note dated October 23, 2023, BofA Securities upgraded an Neutral rating on this stock and boosted its target price from $33 to $52.
This stock has fluctuated between a low of $33.33 and a high of $54.44 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $58.33 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $35.59 at the most recent close of the market. An investor can expect a potential return of 63.89% based on the average IONS price forecast.
Analyzing the IONS fundamentals
Trailing Twelve Months sales for Ionis Pharmaceuticals Inc [NASDAQ:IONS] were 803.56M which represents -7.21% decline. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.46%, Pretax Profit Margin comes in at -0.44%, and Net Profit Margin reading is -0.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.89 and Total Capital is -0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.93.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.04 points at the first support level, and at 34.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.52, and for the 2nd resistance point, it is at 37.46.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ionis Pharmaceuticals Inc [NASDAQ:IONS] is 8.91. Also, the Quick Ratio is 8.82, while the Cash Ratio stands at 1.1. Considering the valuation of this stock, the price to sales ratio is 6.99, the price to book ratio is 8.48.
Transactions by insiders
Recent insider trading involved Swayze Eric, EVP Research, that happened on Nov 12 ’24 when 1194.0 shares were sold. Chief Executive Officer, Monia Brett P completed a deal on Nov 12 ’24 to sell 6630.0 shares. Meanwhile, Director LOSCALZO JOSEPH sold 13508.0 shares on Nov 12 ’24.
